JNJ

Johnson & Johnson [JNJ] Stock Forecast

Q: What is Johnson & Johnson stock symbol ?

Johnson & Johnson is a US stock, located in New brunswick of Nj and trading under the symbol JNJ

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

JNJ Stock Summary

Profit margins (0.38%) are lower than the previous year (0.41%)

JNJ has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

JNJ

Top 10 Correlated Stocks

JNJ

In the News

JNJ Financial details

Company Rating

Strong Buy

Market Cap

355.34B

Income

35.15B

Revenue

93.02B

Book val./share

28.57

Cash/share

9.52

Dividend

4.76

Dividend %

3.23%

Employees

131.9K

Optionable

Shortable

Yes

Earnings

16 Apr 2024

P/E

10.1

Forward P/E

PEG

P/S

3.82

P/B

5.16

P/C

15.52

P/FCF

19.47

Quick Ratio

0.82

Current Ratio

1.16

Debt / Equity

0.43

LT Debt / Equity

0.38

EPS (TTM)

12.71

EPS next Y

EPS next Q

EPS this Y

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

0.22%

EPS Q/Q

-100.28%

SMA20

-6.37%

SMA50

-6.96%

SMA100

-2.65%

Inst Own

55.87%

Inst Trans

0.83%

ROA

21%

ROE

49%

ROC

0.2%

Gross Margin

68%

Oper. Margin

26%

Profit Margin

38%

Payout

33%

Shs Outstand

Shs Float

Target Price

52W Range

144.95-175.97

52W High

-15.58%

52W Low

+2.59%

RSI

Rel Volume

0.8

Avg Volume

7.19M

Volume

5.76M

Perf Week

-0.71%

Perf Month

-7.39%

Perf Quarter

1.46%

Perf Half Y

-5.36%

Beta

0.528

Volatility

1.28%, 5.16%

Prev Close

1.37%

Price

147.73

Change

1.9%

JNJ Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-29	2021-01-03	2022-01-02	2023-01-01	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	31.02	31.37	35.63	36.17	35.38
Net income per share	5.72	5.59	7.93	6.83	14.6
Operating cash flow per share	8.85	8.94	8.89	8.07	9.47
Free cash flow per share	7.53	7.67	7.51	6.55	7.58
Cash per share	7.29	9.57	12.01	8.96	9.52
Book value per share	22.48	24.03	28.12	29.26	28.57
Tangible book value per share	-8.25	-10.07	-2.89	-6.38	-0.81
Share holders equity per share	22.48	24.03	28.12	29.26	28.57
Interest debt per share	10.59	13.47	12.89	15.21	12.7
Market cap	384.33B	412.03B	451.51B	463.74B	377.29B
Enterprise value	394.72B	433.31B	470.77B	489.27B	385.86B
P/E ratio	25.42	28	21.63	25.85	10.73
Price to sales ratio	4.68	4.99	4.81	4.88	4.43
POCF ratio	16.41	17.51	19.29	21.88	16.55
PFCF ratio	19.3	20.41	22.85	26.99	20.68
P/B Ratio	6.46	6.51	6.1	6.04	5.49
PTB ratio	6.46	6.51	6.1	6.04	5.49
EV to sales	4.81	5.25	5.02	5.15	4.53
Enterprise value over EBITDA	17.84	21.3	18.32	20.37	13.15
EV to operating cash flow	16.86	18.41	20.11	23.09	16.93
EV to free cash flow	19.82	21.46	23.83	28.47	21.15
Earnings yield	0.04	0.04	0.05	0.04	0.09
Free cash flow yield	0.05	0.05	0.04	0.04	0.05
Debt to equity	0.47	0.56	0.46	0.52	0.43
Debt to assets	0.18	0.2	0.19	0.21	0.18
Net debt to EBITDA	0.47	1.05	0.75	1.06	0.29
Current ratio	1.26	1.21	1.35	0.99	1.16
Interest coverage	66.07	98.63	133.43	86.66	17.52
Income quality	1.55	1.6	1.12	1.18	1.71
Dividend Yield	0.03	0.03	0.02	0.03	0.03
Payout ratio	0.66	0.71	0.53	0.65	0.33
Sales general and administrative to revenue	0.24	0.24	0.23	0.24	0
Research and developement to revenue	0.14	0.15	0.16	0.16	0.18
Intangibles to total assets	0.52	0.51	0.45	0.5	0.42
Capex to operating cash flow	-0.15	-0.14	-0.16	-0.19	-0.2
Capex to revenue	-0.04	-0.04	-0.04	-0.04	-0.05
Capex to depreciation	-0.5	-0.46	-0.49	-0.58	-0.61
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	53.77	54.97	70.85	67.07	96.89
ROIC	0.21	0.18	0.21	0.17	0.19
Return on tangible assets	0.2	0.17	0.21	0.19	0.36
Graham Net	-24.04	-27.19	-22.69	-26.17	-24.56
Working capital	9.31B	8.74B	15.75B	-508M	7.21B
Tangible asset value	-21.81B	-26.52B	-7.62B	-16.75B	-1.96B
Net current asset value	-52.98B	-60.38B	-47.02B	-55.28B	-45.29B
Invested capital	0.47	0.56	0.46	0.52	0.43
Average receivables	14.29B	14.03B	14.43B	15.72B	15.52B
Average payables	8.04B	9.02B	10.28B	11.38B	10.67B
Average inventory	8.81B	9.18B	9.87B	11.44B	11.83B
Days sales outstanding	64.41	60	59.49	62.13	63.75
Days payables outstanding	113.17	122.04	135.16	137.4	131.48
Days of inventory on hand	119.48	119.98	126.99	146.56	152.63
Receivables turnover	5.67	6.08	6.14	5.88	5.73
Payables turnover	3.23	2.99	2.7	2.66	2.78
Inventory turnover	3.05	3.04	2.87	2.49	2.39
ROE	0.25	0.23	0.28	0.23	0.51
Capex per share	-1.32	-1.27	-1.39	-1.53	-1.89

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2023-01-01	2023-04-02	2023-07-02	2023-10-01	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	9.07	9.39	9.73	8.87	8.89
Net income per share	1.35	-0.03	1.96	10.81	1.68
Operating cash flow per share	2.05	1.24	1.59	3.11	3.27
Free cash flow per share	1.44	0.91	1.17	2.71	2.61
Cash per share	9	12.26	10.86	9.77	9.52
Book value per share	29.39	26.9	28.63	29.59	28.57
Tangible book value per share	-6.41	-8.41	-5.82	0.03	-0.81
Share holders equity per share	29.39	26.9	28.63	29.59	28.57
Interest debt per share	15.24	20.22	17.55	12.54	12.28
Market cap	461.69B	413.19B	428.71B	373.47B	377.3B
Enterprise value	487.22B	439.23B	453.13B	383.67B	385.88B
P/E ratio	32.79	-1.52K	20.84	3.59	23.3
Price to sales ratio	19.48	16.71	16.78	17.5	17.64
POCF ratio	86.3	126.86	102.51	49.87	47.98
PFCF ratio	122.69	172.59	140.19	57.26	60.14
P/B Ratio	6.01	5.83	5.7	5.24	5.49
PTB ratio	6.01	5.83	5.7	5.24	5.49
EV to sales	20.55	17.76	17.74	17.97	18.04
Enterprise value over EBITDA	88.6	50.77	51.25	49.01	64.8
EV to operating cash flow	91.07	134.86	108.35	51.23	49.08
EV to free cash flow	129.48	183.47	148.18	58.83	61.5
Earnings yield	0.01	0	0.01	0.07	0.01
Free cash flow yield	0.01	0.01	0.01	0.02	0.02
Debt to equity	0.52	0.75	0.61	0.42	0.43
Debt to assets	0.21	0.27	0.24	0.18	0.18
Net debt to EBITDA	4.64	3.01	2.76	1.3	1.44
Current ratio	0.99	1.07	1.12	1.21	1.16
Interest coverage	31.03	18.97	15.25	22.72	17.5
Income quality	1.52	-47.9	0.81	1.74	1.9
Dividend Yield	0.01	0.01	0.01	0.01	0.01
Payout ratio	0.84	-43.26	0.6	0.11	0.71
Sales general and administrative to revenue	0.19	0.23	0	0	0
Research and developement to revenue	0.17	0.14	0.15	0.16	0.21
Intangibles to total assets	0.5	0.47	0.48	0.43	0.42
Capex to operating cash flow	-0.3	-0.26	-0.27	-0.13	-0.2
Capex to revenue	-0.07	-0.03	-0.04	-0.05	-0.07
Capex to depreciation	-0.9	-0.46	-0.58	-0.53	-0.86
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	29.84	3.95	35.54	84.85	32.88
ROIC	0.04	0.01	0.04	0.05	0.04
Return on tangible assets	0.04	0	0.05	0.27	0.04
Graham Net	-26.28	-28.14	-25.81	-22.69	-24.56
Working capital	-508M	4.02B	6.4B	9.33B	7.21B
Tangible asset value	-16.75B	-22.15B	-15.28B	83M	-1.96B
Net current asset value	-55.28B	-60.71B	-54.71B	-41.13B	-45.29B
Invested capital	0.52	0.75	0.61	0.42	0.43
Average receivables	16.03B	16.26B	16.56B	15.79B	14.84B
Average payables	10.93B	10.81B	10.18B	9.4B	8.99B
Average inventory	12.08B	12.65B	12.85B	12.04B	11.19B
Days sales outstanding	61.35	59.49	59.11	62.39	62.58
Days payables outstanding	135.64	108.11	115.24	115.61	123.91
Days of inventory on hand	144.68	139.75	142.22	154.95	143.84
Receivables turnover	1.47	1.51	1.52	1.44	1.44
Payables turnover	0.66	0.83	0.78	0.78	0.73
Inventory turnover	0.62	0.64	0.63	0.58	0.63
ROE	0.05	0	0.07	0.37	0.06
Capex per share	-0.61	-0.33	-0.43	-0.4	-0.66

JNJ Dividend History

JNJ Frequently Asked Questions

What is Johnson & Johnson stock symbol ?

Johnson & Johnson is a US stock , located in New brunswick of Nj and trading under the symbol JNJ

What is Johnson & Johnson stock quote today ?

Johnson & Johnson stock price is $147.73 today.

Is Johnson & Johnson stock public?

Yes, Johnson & Johnson is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 7.19M
Market Capitalization 355.34B
Employee 131.9K
CEO Mr. Joaquin Duato
Headquarters New Brunswick,NJ,US
IPO Date 1943-01-02
Website https://www.jnj.com

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.